525 related articles for article (PubMed ID: 23172909)
1. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
[TBL] [Abstract][Full Text] [Related]
2. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS.
Soo KY; Halloran M; Sundaramoorthy V; Parakh S; Toth RP; Southam KA; McLean CA; Lock P; King A; Farg MA; Atkin JD
Acta Neuropathol; 2015 Nov; 130(5):679-97. PubMed ID: 26298469
[TBL] [Abstract][Full Text] [Related]
3. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.
Hart MP; Brettschneider J; Lee VM; Trojanowski JQ; Gitler AD
Acta Neuropathol; 2012 Aug; 124(2):221-30. PubMed ID: 22526021
[TBL] [Abstract][Full Text] [Related]
4. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
Ito D
Rinsho Shinkeigaku; 2012; 52(11):1221-3. PubMed ID: 23196570
[TBL] [Abstract][Full Text] [Related]
5. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
[TBL] [Abstract][Full Text] [Related]
6. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
7. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
Hart MP; Gitler AD
J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
[TBL] [Abstract][Full Text] [Related]
8. Protein disulphide isomerase (PDI) is protective against amyotrophic lateral sclerosis (ALS)-related mutant Fused in Sarcoma (FUS) in in vitro models.
Parakh S; Perri ER; Vidal M; Sultana J; Shadfar S; Mehta P; Konopka A; Thomas CJ; Spencer DM; Atkin JD
Sci Rep; 2021 Sep; 11(1):17557. PubMed ID: 34475430
[TBL] [Abstract][Full Text] [Related]
9. Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase.
Farg MA; Soo KY; Walker AK; Pham H; Orian J; Horne MK; Warraich ST; Williams KL; Blair IP; Atkin JD
Neurobiol Aging; 2012 Dec; 33(12):2855-68. PubMed ID: 22459602
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS.
Baron DM; Matheny T; Lin YC; Leszyk JD; Kenna K; Gall KV; Santos DP; Tischbein M; Funes S; Hayward LJ; Kiskinis E; Landers JE; Parker R; Shaffer SA; Bosco DA
Hum Mol Genet; 2019 Jul; 28(13):2143-2160. PubMed ID: 30806671
[TBL] [Abstract][Full Text] [Related]
11. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
[TBL] [Abstract][Full Text] [Related]
12. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
[TBL] [Abstract][Full Text] [Related]
13. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
[TBL] [Abstract][Full Text] [Related]
14. Directly converted patient-specific induced neurons mirror the neuropathology of FUS with disrupted nuclear localization in amyotrophic lateral sclerosis.
Lim SM; Choi WJ; Oh KW; Xue Y; Choi JY; Kim SH; Nahm M; Kim YE; Lee J; Noh MY; Lee S; Hwang S; Ki CS; Fu XD; Kim SH
Mol Neurodegener; 2016 Jan; 11():8. PubMed ID: 26795035
[TBL] [Abstract][Full Text] [Related]
15. Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates FUS toxicity.
Daigle JG; Krishnamurthy K; Ramesh N; Casci I; Monaghan J; McAvoy K; Godfrey EW; Daniel DC; Johnson EM; Monahan Z; Shewmaker F; Pasinelli P; Pandey UB
Acta Neuropathol; 2016 Apr; 131(4):605-20. PubMed ID: 26728149
[TBL] [Abstract][Full Text] [Related]
16. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).
Nihei Y; Ito D; Suzuki N
J Biol Chem; 2012 Nov; 287(49):41310-23. PubMed ID: 23048034
[TBL] [Abstract][Full Text] [Related]
17. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
[TBL] [Abstract][Full Text] [Related]
18. Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.
McGurk L; Lee VM; Trojanowksi JQ; Van Deerlin VM; Lee EB; Bonini NM
J Neuropathol Exp Neurol; 2014 Sep; 73(9):837-45. PubMed ID: 25111021
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
[TBL] [Abstract][Full Text] [Related]
20. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.
Vance C; Rogelj B; Hortobágyi T; De Vos KJ; Nishimura AL; Sreedharan J; Hu X; Smith B; Ruddy D; Wright P; Ganesalingam J; Williams KL; Tripathi V; Al-Saraj S; Al-Chalabi A; Leigh PN; Blair IP; Nicholson G; de Belleroche J; Gallo JM; Miller CC; Shaw CE
Science; 2009 Feb; 323(5918):1208-1211. PubMed ID: 19251628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
